Agilent Completes Acquisition of Proscia
Business Wire•04/11/2026•09:12 ET
1
Key Highlights
- ➤Agilent (A) completed Proscia acquisition for $240 million cash at closing
- ➤Up to an additional $30 million is payable based on future performance milestones
- ➤Proscia joins Agilent’s Life Sciences and Diagnostics Markets Group
- ➤Proscia adds recurring-revenue digital-pathology software to Agilent’s pathology portfolio
- ➤Proscia’s platform has FDA 510(k) clearance for primary diagnosis
Expert Statements
Padraig McDonnell, President and CEO of Agilent
“We’re pleased to complete our acquisition of Proscia, further strengthening Agilent’s pathology portfolio and establishing a platform for scientific intelligence”
Padraig McDonnell, President and CEO of Agilent
“Proscia’s talented team and leading vendor-agnostic digital-pathology platform enhance our ability to support customers across clinical diagnostics, biopharma, and life-sciences research.”
Padraig McDonnell, President and CEO of Agilent
“Together, Agilent and Proscia are well positioned to advance AI-enabled pathology workflows, accelerate drug discovery and companion-diagnostics solutions, and create long-term value for customers and shareholders.”
Expands Agilent’s pathology portfolio and establishes a platform for scientific intelligence in tissue-based precision medicine
Strengthens Agilent’s ability to support customers across clinical diagnostics, biopharma and life-sciences research
Get started
Create a free account to read the full story.